Review

Developments in Viral Vector-Based Vaccines

Takehiro Ura, Kenji Okuda and Masaru Shimada *

Department of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa Prefecture 236-0004, Japan

* Author to whom correspondence should be addressed; E-Mail: mshimada@yokohama-cu.ac.jp; Tel.: +81-45-787-2794.

Received: 22 April 2014; in revised form: 18 June 2014 / Accepted: 30 June 2014 / Published: 29 July 2014

Abstract: Viral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. During the last several decades, many types of viruses have been developed as vaccine vectors. Each has unique features and parental virus-related risks. In addition, genetically altered vectors have been developed to improve efficacy and safety, reduce administration dose, and enable large-scale manufacturing. To date, both successful and unsuccessful results have been reported in clinical trials. These trials provide important information on factors such as toxicity, administration dose tolerated, and optimized vaccination strategy. This review highlights major viral vectors that are the best candidates for clinical use.

Keywords: viral vector; vaccine; CTL; MVA; adenovirus

1. Introduction

Viral vectors are regarded as potential tools for gene therapy and vaccines. Their utility is based on the ability of viruses to infect cells. In general, the advantages of viral vectors are as follows: (a) high efficiency gene transduction; (b) highly specific delivery of genes to target cells; and (c) induction of robust immune responses, and increased cellular immunity.

The concept of viral vector vaccines is different from that of subunit vaccines, as the latter help prevent infectious diseases by eliciting a humoral response. Recombinant viral vectors have potential for therapeutic use because they enable intracellular antigen expression and induce a robust cytotoxic
T lymphocyte (CTL) response, leading to the elimination of virus-infected cells. Despite their efficacy, viral vectors present unavoidable problems that need to be addressed. In the near future, viral vector-based vaccines may be increasingly used to fight major diseases, such as HIV-1 and malaria. In some vectors, stable expression of the interesting gene is achieved via viral integration mechanisms. Integration into the host genome can lead to cancer. Another obstacle to the clinical use of viral vectors is the presence of pre-existing immunity against the vector. This is caused by previous exposure to the virus and the production of neutralizing antibodies that reduce vaccine efficacy.

The development of viral vectors requires a high biological safety level in order to gain public acceptance. Therefore, non- (or low-) pathogenic viruses are often selected. In most cases, viruses are genetically engineered to reduce or eliminate pathogenicity. Additionally, most viral vectors are replication-defective. For example, in adenovirus-based vectors, the E1A and E1B encoding regions, which are needed for replication in infected cells, are deleted and replaced with the target gene.

When using a viral vector, it is important to assess the potential implications by understanding the epidemiological and virological characteristics. In this review, we describe several representative viral vectors with respect to risk and benefit, optimized vector-design attempts, and clinical results. Moreover, we discuss the combined use of viral vectors in prime-boost vaccination regimens.

2. Summary of Viral Vectors

The concept of the viral vector was introduced in 1972. Jackson et al. created recombinant DNA from the SV40 virus by genetic engineering [1]. Subsequently, Moss et al. reported the use of vaccinia virus as a transient gene expression vector in 1982 [2,3]. Several types of viral vectors have been developed, and they have been used in animal studies and clinical trials.

The specific properties of a vector are determined by the virus from which it derives. Each vector has distinct advantages and disadvantages (Table 1). Vaccinia virus and adenovirus are the most widely used vectors because they can induce a robust immune response, specifically involving CTL, against the expressed foreign antigens. Generally, viral vectors achieve high immunogenicity without an adjuvant. Viral components stimulate the innate immune response, leading to the production of interferons and inflammatory cytokines [4].

Viral vector-based vaccines require assessment of efficacy and safety, including immunogenicity, genetic stability, ability to evade pre-existing immunity, replication deficiency or attenuation, and genotoxicity. Additionally, the cost-effectiveness must also be evaluated because infectious diseases are a problem in developing countries. Thus, it is necessary to consider the large-scale manufacturing of viral vectors. Typically, the manufacturing of viral vectors involves propagation in suitable cell lines.

The European Medicines Agency (EMA) recently provided guidelines on quality for non-clinical and clinical aspects [5]. These guidelines offer useful recommendations for the effective administration of live, recombinant viral vector-based infectious vaccines.
Table 1. Advantages and disadvantages of major viral vectors.

| Virus               | Advantages                                                                 | Disadvantages                                                                 | Major Clinical/Preclinical Studies |
|---------------------|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------|-----------------------------------|
| Retrovirus          | Long-term gene expression                                                   | Generation of replication-competent virus                                     | [6]                               |
|                     |                                                                             | Potential for tumorigenesis                                                   |                                   |
|                     |                                                                             | Infects dividing cells only                                                   |                                   |
| Lentivirus          | Long-term gene expression                                                   | Replication-competent virus                                                   | [7, 8]                            |
|                     |                                                                             | Potential for tumorigenesis                                                   |                                   |
|                     | Infects non-dividing and dividing cells                                     |                                                                               |                                   |
|                     | High immunogenicity                                                        |                                                                               |                                   |
| Vaccinia virus      | Safety: used as a smallpox vaccine                                          | Pre-existing immunity                                                        | [9]                               |
|                     | High titer production                                                      |                                                                               |                                   |
|                     | High immunogenicity                                                        |                                                                               |                                   |
| Adenovirus          | Safety: used in many clinic trails                                          | Pre-existing immunity                                                        | [10]                              |
|                     | High titer production                                                      |                                                                               |                                   |
| Adeno-associated    | Long-term gene expression                                                   | Low titer production                                                          | [11]                              |
| virus               | Non-pathogenic virus                                                       |                                                                               |                                   |
|                     | Induces a unique CTL response                                               | Pre-existing immunity                                                        |                                   |
| Cytomegalovirus     | Protects against SIV infection in an animal model                           | Risk of pathogenesis in specific individuals                                  | [12]                              |
| Sendai virus        | High immunogenicity                                                        | Pre-existing immunity                                                        | [13]                              |

3. Viral Vectors

3.1. Poxviruses as Vaccine-vectors

Vaccinia virus, a member of the poxvirus family, is a large, complex, enveloped virus. The virus is traditionally used for the smallpox vaccine, and its efficacy and safety have been demonstrated. During vaccine development, highly attenuated vaccinia virus strains have been generated, including replication-competent (LC16m8) and replication-deficient (NYVAC, ALVAC, TROVAC and MVA) strains. These strains are most frequently used for vaccinia virus vector production, although numerous strains of vaccinia virus exist in humans and animals.

Modified vaccinia Ankara (MVA) is a highly attenuated strain derived from the vaccinia strain Ankara. MVA has lost the 15% of the vaccinia genome and the ability to replicate in mammalian cells. MVA has been safely administered to over 120,000 individuals as a smallpox vaccine [14]. For priming, $1 \times 10^6$ infectious units (IU)/dose of MVA was administered. LC16m8 is derived from the Lister strain, which has a narrow host range for replication. LC16m8 has been evaluated in 50,000 children without severe side effects [15]. NYVAC is generated from the Copenhagen strain by genetic deletion. ALVAC and TROVAC are derived from the canarypox and fowlpox viruses, respectively.

Vaccinia virus has a linear, double-stranded DNA genome approximately 190 kb in length. Because of its large size, the viral genome has a high capacity for foreign gene insertion. Indeed, the vector accepts approximately 25 kb of foreign genetic material.
The first vaccinia virus-based gene expression vector was described in 1982 [2,3]. Since then, many studies have shown that vaccinia virus vector-based vaccines can induce a robust immune response against foreign antigens because of high transgene expression [16,17]. In addition, the vectors activate a strong innate immune response mediated by Toll-like receptors (TLRs) and the inflammasome, resulting in an adjuvant effect [18,19].

Currently, many clinical trials are evaluating the use of vaccinia virus vectors. Various diseases are targets for vaccines, such as HIV-1 [20–22], hepatitis [23], influenza [24], malaria [25,26], tuberculosis (TB) [27], and cancer [28]. Most of the vaccines are intended to induce a robust CTL response against foreign antigen. In clinical trials, vaccinia virus vectors were well tolerated, although severe adverse events were observed in some studies when the MVA vector was administered at a dose over $10^8$ pfu [29]. In 2009, a Phase III ALVAC-based HIV-1 vaccine demonstrated a modest protective effect. This trial was the first to provide evidence for the efficacy of an HIV-1 vaccine in a large-scale study [9].

Another advantage of vaccinia virus is that a large-scale manufacturing method was established for the production of the smallpox vaccine. For example, Bavarian Nordic A/S produced 20 million doses of smallpox vaccine (named IMVAMUNE®), which were delivered to the U.S. government for emergency use [30]. For large-scale manufacture, the MVA vector is generally produced in chick embryo fibroblast (CEF) cells. Specifically, the plasmid with the recombinant transgene is transfected into CEF cells using vaccinia virus. The recombinant vectors that propagate in the CEF cells are purified by centrifugation. Recently, AGE1.CR [31] and EB66 [32] cell lines have been developed for improved MVA production.

A presumed disadvantage of vaccinia virus vectors is the limited immunogenicity observed in smallpox-vaccinated individuals. Pre-existing immunity against the poxvirus may reduce the vaccine’s efficacy [33]. According to some clinical trials, the effect of pre-existing immunity is moderate [34,35].

Today, efforts to improve vaccinia virus vectors continue. To improve immunogenicity, the development of stronger promoters and the removal of immunomodulatory MVA genes have been reported [36,37].

Ultimately, vaccinia virus vectors have the potential to be employed as highly immunogenic and well-tolerated vaccines. Their use has historical precedent in the smallpox vaccine, and a manufacturing process has been established.

3.2. Adenovirus Vectors

Approximately 50 human adenovirus (Ad) serotypes have been identified. Among them, human Ad serotype 5 (Ad5) has been widely investigated as a gene delivery vector because it can be easily produced in high titers. Ad5 contains a 36-kb double-stranded, linear DNA genome; it has a capsid shell with hexon and penton structures and no envelope. Because the Ad fiber protein mediates Ad binding to the coxsackievirus and Ad receptor (CAR), it is a major determinant of viral tropism. Various clinical syndromes are causes by Ad infection, including acute respiratory disease, pharyngoconjunctival fever, and gastroenteritis.
Recombinant Ad vectors are widely used because of their high transduction efficiency, high level of transgene expression, and broad range of viral tropism. They can infect both dividing and non-dividing cells.

Most Ad vectors are replication-defective because of deletion of the \textit{E1A} and \textit{E1B} viral gene region. Often, the \textit{E3} genes are also deleted to provide space for the transgene. A popular method for Ad vector production involves two steps. First, the Ad vector plasmid is transfected into E1-complementing cell lines (the 293 cell lines are frequently used). The Ad vector then propagates in the infected 293 cells in culture. Second, the vector is collected from infected cells and purified by ultracentrifugation. Because most people have been exposed to an Ad serotype, the presence of pre-existing anti-Ad immunity is a disadvantage of the Ad vector. Ad contains three main structural proteins, hexon, penton, and fiber. These proteins are the major targets of the humoral and cellular immune responses against Ad5 [38,39]. Antibodies against the hypervariable regions (HVRs) of the hexon protein dominate the neutralizing responses [40]. Modification of these HVRs and the fiber knob domain has been investigated as a way to evade pre-existing immunity [41–43].

Although replication-defective Ad has reduced its overall virulence, a further improvement in the clinical safety profile of Ad vectors is required. For example, because CAR is expressed at a high level in hepatocytes, Ad5-based vectors have a strong tropism for liver parenchymal cells, which increases hepatotoxicity [44]. Modification of the fiber protein of Ad can alter its tropism and reduce liver toxicity [45]. Another approach is modulation of the host immune response by reducing viral gene expression. Deletion of the E2 and E4 viral gene regions lowers toxicity by reducing the vector-derived immune response in infected cells. This vector is called a 2nd generation Ad vector [46].

Modification of the Ad fiber protein also improves the efficiency of gene transduction because fiber protein determines the virus’s tropism. The RGD-fiber Ad vector, which incorporates an Arg-Gly-Asp (RGD) peptide into the fiber knob domain, enhances transduction into T cells and dendritic cells [47]. Our group generated a highly immunogenic chimeric Ad5 vector that expresses the Ad35 fiber protein [45].

Recombinant Ad vector-based vaccines have been examined in clinical trials against HIV-1 [48,49], influenza [50], and solid tumors [51]. Ad vectors are well tolerated, and a Phase I study of an HIV-1 vaccine identified $10^{10}$ virus particles (VP) as the best-tolerated dose [52]. Despite these efforts, a major Phase IIb trial failed, as the Ad vector further amplified a pre-existing immune response against Ad5, during a STEP Study [10]. This result revealed that vector-based vaccines such as the above could provide conducive environments for HIV-1 replication, thereby contradicting the clinical safety outcomes of a previous HIV-1 study [53]. On the contrary, a Phase I Ad5-based TB vaccine demonstrated immunogenic efficacy, in spite of a pre-existing anti-Ad immunity [54]. In order to evaluate the safe use of Ad-based vectors, a better understanding of the host immune response against different antigens seems necessary.

3.3. Adeno-Associated Virus Vectors

Adeno-associated virus (AAV) is a small, single-stranded DNA virus that lacks an envelope. AAV is a nonpathogenic viral vector; the virus has low immunogenicity and has never shown any pathogenicity. The AAV genome integrates into the human genome at a specific site on chromosome
19q. The integration involves the Rep region and inverted terminal repeats (ITR) at both ends of the viral genome. Thus, AAV vectors provide long-term transgene expression. The virus can infect both dividing and non-dividing cells and has broad tropism for many different cell types.

Twelve AAV serotypes in humans and more than 100 AAV serotypes in diverse animal species, including nonhuman primates, canines, and fowl, have been found. AAV2 is commonly used as a vector in preclinical and clinical studies. Each serotype has unique receptors, and the tissue specificity is determined by the capsid serotype. For instance, AAV-1 and AAV-7 are best for the transduction of skeletal muscle [55,56]. AAV6 and AAV5 infect airway epithelial cells efficiently [57,58]. The AAV vector also efficiently transfers transgenes into the brain [59], muscle [60], lung [61], gut [62], liver [63], and eye [64].

Generally, recombinant AAV vectors are generated by deletion of the Rep and Cap coding regions between the ITRs. These regions are used for endogenous transgene expression. Owing to the deletion of these regions, AAV vectors cannot integrate into the host genome, and their DNA also persists in an episomal form. This preferable feature in the AAV vectors boosts their safety profile, by preventing the onset of tumorigenesis. The AAV vector has a transgene capacity of approximately 4.5 kb, which is lower than other viral vectors, including herpes virus (30 kb), adenovirus (8–10 kb), and retrovirus (7–8 kb).

During manufacturing, AAV requires a helper virus to replicate. Thus, AAV vector production requires complementation of adenovirus regions VA, E1, E2, and E4. These proteins are provided either by plasmid co-transfection or by adenovirus infection of host cells. Compared to other viral vectors, the AAV vector has low-titer production efficiency. Therefore, high-efficacy and large-scale production methods have been developed. For example, the use of baculovirus system enhances AAV vector production [65]. Baculovirus systems easily provide helper functions for vector production and insect cell growth [66].

An alternative way to compensate for low-titer production is to reduce the administration dose. In human clinical trials, a dose of 10^{12}–10^{13} genome copies/kg body weight of AAV is commonly administered. To reduce the dose, it is necessary to improve the transduction efficiency and increase the immunogenicity of the vector. To enhance AAV immunogenicity, capsid modification vectors have been developed. AAV comprises three structural capsid proteins, VP1, VP2, and VP3. Generating of mixture capsids from different serotypes can alter tropism and increase the efficiency of gene delivery to target cells or tissues [67].

When using AAV vectors, assessment of the risk of genetic toxicity is important because AAV vector may require host genome integration for viral gene expression. With regard to the tumorigenicity of AAV vectors, conflicting results have been reported in animal studies [68,69].

Numerous clinical studies have investigated the use of AAV vectors for gene therapy in the treatment of Parkinson’s disease [70], Alzheimer’s disease [71,72], cardiac disease [73], and prostate cancer [74]. In 2012, the EMA approved an AAV1 vector to deliver the lipoprotein lipase (LPL) gene in patients with LPL deficiency [11]. Many animal studies have examined vaccine vectors against HIV-1 [75–77], influenza [78], and papillomavirus [79]. These animal studies indicate a potential for AAV-based vaccines. However, human clinical trials are rare because AAV vectors induce weak humoral and cellular immunity compared to other viral vectors (e.g., Ad, MVA). Moreover, infectious vaccines normally target a large population, healthy people, and a wide range of ages, including
children and adolescents. Thus, AAV vector-based vaccines require stronger safety measures and greater cost-effectiveness than AAV-based gene therapies.

3.4. Retrovirus Vectors

A retrovirus is an enveloped, single-stranded RNA virus that contains reverse transcriptase. Retrovirus vectors are typically replication-defective, and most are of murine or avian origin. Among them, the Moloney murine leukemia virus (MoMLV) has been widely investigated. Retroviruses require genome integration for gene expression. Thus, retrovirus vectors similar with AAV, provide long-term gene expression. The genome size is approximately 7–11 kb and the vector can easily harbor 7–8 kb long foreign DNA inserts. Retroviruses display low immunogenicity and most patients do not show any pre-existing immunity to retroviral vectors. However, retroviruses are associated with various diseases. For example, MoMLV causes leukemia and lymphoma, although it is species-specific.

In clinical studies, retroviral vector-based gene therapy has been implemented in patients with an X-linked severe combined immunodeficiency (SCID-X1) or malignant glioma [6,80]. The therapy for SCID-X1 demonstrated high efficacy. However, four out of the 10 treated patients eventually developed lymphoma [81]. This safety issue also arose during preclinical trials [82,83]. The onset of tumorigenesis resulted from the integration of viral LTRs into proto-oncogenes. As retroviral vectors preferentially integrate near cellular gene promoters that regulate cell replication, non-integrating and self-inactivating (SIN) vectors could potentially reduce the risk of tumorigenesis [84,85]. SIN vectors contain partially deleted LTRs and are rendered inactive during vector production. Owing to this reason, SIN vectors have been recommended for clinical trials targeting SCID-X1 [86].

3.5. Lentivirus Vectors

Lentiviruses constitute a subclass of retroviruses. Lentiviruses infect both non-dividing and dividing cells, whereas retroviruses only infect dividing cells. Thus, lentiviruses generally exhibit broader tropism than retroviruses. Several proteins such as tat and rev regulate the replication of lentiviruses. These regulatory proteins are absent in retroviruses. HIV is a well-known lentivirus that has been engineered into a transgene delivery vector. The advantages of lentiviral vector are similar to those of retroviral vectors. Although lentiviruses can potentially trigger tumorigenesis, the risk is lower than that of retroviral vectors, as the integration sites of lentiviruses are away from the sites harboring cellular promoters.

As of now, several types of HIV-based vectors have been generated, by deleting the HIV viral envelope and some of the regulatory genes not required during vector production. Instead of parental envelope, several chimeric or modified envelope vectors are generated because it determines the cell and tissue specificity. For example, VSV/HIV-1-based vectors contain the envelope glycoprotein derived from the vesicular stomatitis virus (VSV), and are used during vaccination owing to the broad range tropism exhibited by VSV [87]. Envelopes derived from filovirus [88], MoMLV [89] and measles [90] have also been used in designing therapeutic vectors. An HIV-1 based vector called VRX496 (developed by VIRxSYS Corporation) was used for HIV-1 gene therapy during recent clinical trials. These trials demonstrated a favorable safety profile and a potential application in gene therapy [7,8].
The virulence of HIV-1 raises serious concerns. Feline immunodeficiency virus (FIV)-based vectors have hence been developed, as the virulence of lentiviruses is highly species-specific [91]. FIV vector vaccines developed to combat HIV-1 and the Herpes simplex virus have demonstrated significant potential [92,93].

### 3.6. Cytomegalovirus Vectors

Cytomegalovirus (CMV) is a member of the herpesviruses. Several species-specific CMVs have been identified. Among them, human CMV (HCMV), also known as human herpesvirus type 5, has been most thoroughly investigated. HCMV contains a 235-kb double-stranded linear DNA genome, which is surrounded by a capsid. The envelope contains the glycoproteins gB and gH, which bind to cellular receptors. CMV often goes unnoticed because its pathogenicity is mild in people who are immunologically healthy. Pathogenesis is a risk only in pregnant woman and immunocompromised individuals.

Hansen *et al.* reported that a rhesus CMV (RhCMV) vector-based vaccine protected against SIV infection and eliminated SIV [12]. Interestingly, the RhCMV-based vaccine elicits a unique MHC class II-restricted CTL response that recognizes a broad range of antigen epitopes. Such features have not been observed with MVA- or Ad5-based vaccines [94]. This HCMV vector-based vaccine has been recently expected to one of the best effective vaccine against HIV infection.

### 3.7. Sendai Virus Vectors

Sendai virus (SeV) is an enveloped, single-stranded RNA virus of the family Paramyxovirus. It is also known as murine parainfluenza virus type 1 or hemagglutinating virus of Japan. SeV causes bronchopneumonia in mice, but is considered non-pathogenic in humans. However, as SeV is highly homologous to the human parainfluenza virus type 1 (hPIV-1) virus, a pre-existing immunity against hPIV-1 also works against SeV. Hara *et al.* showed that SeV-specific neutralizing antibodies are detected in a majority of adult people [95]. The SeV genome encodes six protein and two envelope glycoproteins, HN and F proteins, that mediate cell entry. These proteins also determine its tropism. Thus, lack of F protein results in a replication-defective virus and improves the safety of the vector. The SeV vector produced in the packaging cell expresses the F protein. An F gene-deleted and transgene-inserted genome is transfected into the packaging cell. Additionally, SeV contains RNA dependent RNA polymerase and viral genome localizes to the cytoplasm. This ensures that fast gene expression occurs soon after infection and the genotoxic advantage of SeV. The SeV vector exhibits highly efficient gene transfer and transduces both dividing and non-dividing cells. The SeV vector efficiently transduces human airway epithelial cells, and it is often administered by a mucosal (oral and nasal) route. Intranasal administration can potentially reduce the influence of a pre-existing immunity to SeV, as compared to intramuscular administration [96]. Compared to other viral vectors, its transgene capacity (3.4 kb) is low, which limits the use of the SeV vector.

The SeV vector has been used for gene therapy and in a vaccine in human trials [13,97]. A clinical trial of an SeV vector-based HIV-1 vaccine is underway (NCT01705990). The trial is using a replicating SeV vector, rather than a non-replicating vector, in order to elicit a more effective immune response.
4. Combination Vaccine Regimens

The prime-boost regimen is a common method for vaccination. As mentioned above, multiple vaccinations with a single viral vector are considered ineffective because of the induction of anti-vector immunity. To overcome this problem, a DNA prime and viral vector boost strategy is often used. Many studies have shown that this strategy induces a protective CTL response. Another approach is the combined use of different types of viral vectors. This approach has the potential to induce a more robust immune response than any other method. As a combination regimen, MVA and Ad vectors are generally used because both vectors have high immunogenicity. These vectors elicit a much higher immune response when using a prime-boost regimen [98,99]. However, our group found that co-administration of Ad and MVA vectors suppressed transgene expression via soluble factors secreted by virus-infected cells. In an in vitro experiment, the MVA vector was shown to infect cell culture supernatant suppressed Ad vector transgene expression [100].

Another approach is to combine a viral vector with a currently available vaccine. For instance, the BCG vaccine, a live, attenuated vaccine against TB, induces limited protection, especially in adolescents and adults. The ability of an MVA85A boost regimen to enhance protective immunity following BCG vaccination was examined. A Phase IIb trial of MVA85A failed, but the use of viral vectors to enhance a priming immunization remains a possibility [27].

5. Conclusions

In conclusion, several viral vectors have been used in vaccine production and in gene therapy. In this review, we have described several candidate viral vectors with potential clinical applications. The MVA vector and the Ad vector are the most preferred therapeutic vectors against HIV-1. The CMV vector elicits a unique immune response, whereas the SeV vector can potentially induce mucosal immunity. Viral vector-based vaccines can be easily manufactured alongside traditional vaccines in large manufacturing units, and their safety profiles can be tested easily. The MVA virus, the poliovirus, and the measles virus, have all been investigated for viral vector use.

The first clinical trial of a therapeutic retroviral vector took place in 1990. Subsequent clinical studies have raised serious concerns regarding genotoxicity, mainly due to possible viral genome integration. The AAV vector has the ability to express episomal genes without integrating itself into the host genome, and has hence been approved by the EMA for clinical use.

Today, numerous viral vectors are being investigated. Each vector has unique advantages, as described above. Exploiting their advantages will increase their potential and hasten the clinical use of viral vector-based vaccines. These vaccines can potentially induce a robust immune response in tissues and cells and achieve targeted delivery. Early-phase trials show that they can be tolerated well in humans. Ongoing efforts to design and optimize vaccination regimens will eventually result into the development of new vaccines.
Acknowledgments

The work reported in this review was supported in part by a grant-in-aid from the Ministry of Education, Science, Sports, Culture of Japan and the Ministry of Health and Welfare of Japan (No. 26462531).

Author Contributions

Takehiro Ura, Kenji Okuda and Masaru Shimada contribute for writing manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Jackson, D.A.; Symons, R.H.; Berg, P. Biochemical method for inserting new genetic information into DNA of Simian Virus 40: Circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc. Natl. Acad. Sci. USA 1972, 69, 2904–2909.
2. Mackett, M.; Smith, G.L.; Moss, B. Vaccinia virus: A selectable eukaryotic cloning and expression vector. Proc. Natl. Acad. Sci. USA 1982, 79, 7415–7419.
3. Panicali, D.; Paoletti, E. Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Natl. Acad. Sci. USA 1982, 79, 4927–4931.
4. Akira, S.; Uematsu, S.; Takeuchi, O. Pathogen recognition and innate immunity. Cell 2006, 124, 783–801.
5. Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines. Available online: http://www.google.co.jp/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0 CB4QfAA=&url=http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FScientific_guideline%2F2010%2F08%2FWC500095721.pdf&ei=ekqeU4KVBZfh8AXy04CI DQ&usg=AFQjCNiNGp5tFdi8xYzi_hgA9HS6-eczxN7A&bvm=bv.68911936,d.dGc (accessed on June 24, 2009).
6. Cavazzana-Calvo, M.; Hacein-Bey, S.; de Saint Basile, G.; Gross, F.; Yvon, E.; Nusbaum, P.; Selz, F.; Hue, C.; Certain, S.; Casanova, J.L.; et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288, 669–672.
7. Tebas, P.; Stein, D.; Binder-Scholl, G.; Mukherjee, R.; Brady, T.; Rebello, T.; Humeau, L.; Kalos, M.; Papasavvas, E.; Montaner, L.J.; et al. Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood 2013, 121, 1524–1533.
8. Dropulic, B.; Hermankova, M.; Pitha, P.M. A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc. Natl. Acad. Sci. USA 1996, 93, 11103–11108.
9. Rerks-Ngarm, S.; Pitisuttithum, P.; Nitayaphan, S.; Kaewkungwal, J.; Chiu, J.; Paris, R.; Premtri, N.; Namwat, C.; de Souza, M.; Adams, E.; et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361, 2209–2220.
10. Sekaly, R.P. The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development? *J. Exp. Med.* 2008, 205, 7–12.

11. Ferreira, V.; Petry, H.; Salmon, F. Immune responses to AAV-Vectors, the glybera example from bench to bedside. *Front. Immunol.* 2014, 5, doi:10.3389/fimmu.2014.00082.

12. Hansen, S.G.; Ford, J.C.; Lewis, M.S.; Ventura, A.B.; Hughes, C.M.; Coyne-Johnson, L.; Whizin, N.; Oswald, K.; Shoemaker, R.; Swanson, T.; *et al.* Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. *Nature* 2011, 473, 523–527.

13. Slobod, K.S.; Shenep, J.L.; Lujan-Zilbermann, J.; Allison, K.; Brown, B.; Scroggs, R.A.; Portner, A.; Coleclough, C.; Hurwitz, J.L. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. *Vaccine* 2004, 22, 3182–3186.

14. Stickl, H.; Hochstein-Mintzel, V.; Mayr, A.; Huber, H.C.; Schafer, H.; Holzner, A. MVA vaccination against smallpox: Clinical tests with an attenuated live vaccinia virus strain (MVA) (author’ transl). *Dtsch. Med. Wochenschr.* 1974, 99, 2386–2392.

15. Hashizume, S. A new attenuated strain of vaccinia virus, LC 16m8: Basic information. *J. Clin. Virol.* 1975, 3, 229–235.

16. Gomez, C.E.; Najera, J.L.; Krupa, M.; Perdiguero, B.; Esteban, M. MVA and NYVAC as vaccines against emergent infectious diseases and cancer. *Curr. Gene Ther.* 2011, 11, 189–217.

17. Sutter, G.; Staib, C. Vaccinia vectors as candidate vaccines: The development of modified vaccinia virus Ankara for antigen delivery. *Curr. Drug Targets Infect. Disord.* 2003, 3, 263–271.

18. Zhu, J.; Martinez, J.; Huang, X.; Yang, Y. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. *Blood* 2007, 109, 619–625.

19. Price, P.J.; Torres-Dominguez, L.E.; Brandmuller, C.; Sutter, G.; Lehmann, M.H. Modified vaccinia virus Ankara: Innate immune activation and induction of cellular signalling. *Vaccine* 2013, 31, 4231–4234.

20. Gomez, C.E.; Najera, J.L.; Perdiguero, B.; Garcia-Arriaza, J.; Sorzano, C.O.; Jimenez, V.; Gonzalez-Sanz, R.; Jimenez, J.L.; Munoz-Fernandez, M.A.; Lopez Bernaldo de Quiros, J.C.; *et al.* The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. *J. Virol.* 2011, 85, 11468–11478.

21. Garcia, F.; Bernaldo de Quiros, J.C.; Gomez, C.E.; Perdiguero, B.; Najera, J.L.; Jimenez, V.; Garcia-Arriaza, J.; Guardo, A.C.; Perez, I.; Diaz-Brito, V.; *et al.* Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). *Vaccine* 2011, 29, 8309–8316.

22. Bakari, M.; Aboud, S.; Nilsson, C.; Francis, J.; Buma, D.; Moshiro, C.; Aris, E.A.; Lyamuya, E.F.; Janabi, M.; Godoy-Ramirez, K.; *et al.* Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. *Vaccine* 2011, 29, 8417–8428.

23. Cavenaugh, J.S.; Awi, D.; Mendy, M.; Hill, A.V.; Whittle, H.; McConkey, S.J. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. *PLoS One* 2011, 6, e14626.
24. Berthoud, T.K.; Hamill, M.; Lillie, P.J.; Hwenda, L.; Collins, K.A.; Ewer, K.J.; Milicic, A.; Poyntz, H.C.; Lambe, T.; Fletcher, H.A.; et al. Potent CD8 T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin. Infect. Dis. 2011, 52, 1–7.

25. Bejon, P.; Ogada, E.; Mwangi, T.; Milligan, P.; Lang, T.; Fegan, G.; Gilbert, S.C.; Peshu, N.; Marsh, K.; Hill, A.V. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS One 2007, 2, e707.

26. Sheehy, S.H.; Duncan, C.J.; Elias, S.C.; Biswas, S.; Collins, K.A.; O’Hara, G.A.; Halstead, F.D.; Ewer, K.J.; Mahungu, T.; Spencer, A.J.; et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One 2012, 7, e31208.

27. Tameris, M.D.; Hatherill, M.; Landry, B.S.; Scriba, T.J.; Snowden, M.A.; Lockhart, S.; Shea, J.E.; McClain, J.B.; Hussey, G.D.; Hanekom, W.A.; et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial. Lancet 2013, 381, 1021–1028.

28. Chan, W.M.; Rahman, M.M.; McFadden, G. Oncolytic myxoma virus: The path to clinic. Vaccine 2013, 31, 4252–4258.

29. Gilbert, S.C. Clinical development of modified vaccinia virus Ankara vaccines. Vaccine 2013, 31, 4241–4246.

30. Frey, S.E.; Winokur, P.L.; Salata, R.A.; El-Kamary, S.S.; Turley, C.B.; Walter, E.B., Jr.; Hay, C.M.; Newman, F.K.; Hill, H.R.; Zhang, Y.; et al. Safety and immunogenicity of IMVAMUNE(R) smallpox vaccine using different strategies for a post event scenario. Vaccine 2013, 31, 3025–3033.

31. Jordan, I.; Northoff, S.; Thiele, M.; Hartmann, S.; Horn, D.; Howing, K.; Bernhardt, H.; Oehmke, S.; von Horsten, H.; Rebeski, D.; et al. A chemically defined production process for highly attenuated poxviruses. Biologicals 2011, 39, 50–58.

32. Brown, S.W.; Mehtali, M. The avian EB66(R) cell line, application to vaccines, and therapeutic protein production. PDA J. Pharm. Sci. Technol. 2010, 64, 419–425.

33. Cooney, E.L.; Collier, A.C.; Greenberg, P.D.; Coombs, R.W.; Zarling, J.; Arditti, D.E.; Hoffman, M.C.; Hu, S.L.; Corey, L. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991, 337, 567–572.

34. Gudmundsdotter, L.; Nilsson, C.; Brave, A.; Hejdeman, B.; Earl, P.; Moss, B.; Robb, M.; Cox, J.; Michael, N.; Marovich, M.; et al. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009, 27, 4468–4474.

35. Harrop, R.; Connolly, N.; Redchenko, I.; Valle, J.; Saunders, M.; Ryan, M.G.; Myers, K.A.; Drury, N.; Kingsman, S.M.; Hawkins, R.E.; et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A phase I/II trial. Clin. Cancer Res. 2006, 12, 3416–3424.

36. Davison, A.J.; Moss, B. New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. Nucleic Acids Res. 1990, 18, 4285–4286.
37. Falivene, J.; Del Medico Zajac, M.P.; Pascutti, M.F.; Rodriguez, A.M.; Maeto, C.; Perdiguer, B.; Gomez, C.E.; Esteban, M.; Calamante, G.; Gherardi, M.M. Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. *PLoS One* **2012**, *7*, e32220.

38. Sumida, S.M.; Truit, D.M.; Lemckert, A.A.; Vogels, R.; Custers, J.H.; Addo, M.M.; Lockman, S.; Peter, T.; Peyerl, F.W.; Kishko, M.G.; *et al.* Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. *J. Immunol.* **2005**, *174*, 7179–7185.

39. Wohlfart, C. Neutralization of adenoviruses: Kinetics, stoichiometry, and mechanisms. *J. Virol.* **1988**, *62*, 2321–2328.

40. Crawford-Miksza, L.; Schnurr, D.P. Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. *J. Virol.* **1996**, *70*, 1836–1844.

41. Roberts, D.M.; Nanda, A.; Havenga, M.J.; Abbin, P.; Lynch, D.M.; Ewald, B.A.; Liu, J.; Thorner, A.R.; Swanson, P.E.; Gorgone, D.A.; *et al.* Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. *Nature* **2006**, *441*, 239–243.

42. Ura, T.; Yoshida, A.; Xin, K.Q.; Yoshizaki, S.; Yashima, S.; Abe, S.; Mizuguchi, H.; Okuda, K. Designed recombinant adenovirus type 5 vector induced envelope-specific CD8+ cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1. *J. Gene Med.* **2009**, *11*, 139–149.

43. Abe, S.; Okuda, K.; Ura, T.; Kondo, A.; Yoshida, A.; Yoshizaki, S.; Mizuguchi, H.; Klinman, D.; Shimada, M. Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. *J. Gene Med.* **2009**, *11*, 570–579.

44. Yang, Y.; Nunes, F.A.; Berencsi, K.; Furth, E.E.; Gonczol, E.; Wilson, J.M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 4407–4411.

45. Xin, K.Q.; Jounai, N.; Someya, K.; Honma, K.; Mizuguchi, H.; Naganawa, S.; Kitamura, K.; Hayakawa, T.; Saha, S.; Takeshita, F.; *et al.* Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. *Gene Ther.* **2005**, *12*, 1769–1777.

46. Gao, G.P.; Yang, Y.; Wilson, J.M. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. *J. Virol.* **1996**, *70*, 8934–8943.

47. Okada, N.; Iyama, S.; Okada, Y.; Mizuguchi, H.; Hayakawa, T.; Nakagawa, S.; Mayumi, T.; Fujita, T.; Yamamoto, A. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. *Cancer Gene Ther.* **2005**, *12*, 72–83.

48. Hammer, S.M.; Sobiesczyn, M.E.; Janes, H.; Karuna, S.T.; Mulligan, M.J.; Grove, D.; Koblin, B.A.; Buchbinder, S.P.; Keefer, M.C.; Tomaras, G.D.; *et al.* Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. *N. Engl. J. Med.* **2013**, *369*, 2083–2092.

49. Kibuuka, H.; Kimutai, R.; Maboko, L.; Sawe, F.; Schunk, M.S.; Kroidl, A.; Shaffer, D.; Eller, L.A.; Kibaya, R.; Eller, M.A.; *et al.* A phase 1/2 study of a multiclade HIV-1 DNA
plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J. Infect. Dis. 2010, 201, 600–607.
50. Gurwith, M.; Lock, M.; Taylor, E.M.; Ishioka, G.; Alexander, J.; Mayall, T.; Ervin, J.E.; Greenberg, R.N.; Strout, C.; Treanor, J.J.; et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: A randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect. Dis. 2013, 13, 238–250.
51. Diaz, C.M.; Chiappori, A.; Aurisicchio, L.; Bagchi, A.; Clark, J.; Dubey, S.; Fridman, A.; Fabregas, J.C.; Marshall, J.; Scarselli, E.; et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J. Transl. Med. 2013, 11, doi:10.1186/1479-5876-11-62.
52. Catanzaro, A.T.; Koup, R.A.; Roederer, M.; Bailier, R.T.; Enama, M.E.; Moodie, Z.; Gu, L.; Martin, J.E.; Novik, L.; Chakrabarti, B.K.; et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 2006, 194, 1638–1649.
53. Perreau, M.; Pantaleo, G.; Kremer, E.J. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J. Exp. Med. 2008, 205, 2717–2725.
54. Smaill, F.; Jeyanathan, M.; Smieja, M.; Medina, M.F.; Thanthrige-Don, N.; Zgianiazc, A.; Yin, C.; Heriazon, A.; Damjanovic, D.; Puri, L.; et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci. Transl. Med. 2013, 5, doi:10.1126/scitranslmed.3006843.
55. Gao, G.P.; Alvira, M.R.; Wang, L.; Calcedo, R.; Johnston, J.; Wilson, J.M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA 2002, 99, 11854–11859.
56. Xiao, W.; Chirmule, N.; Berta, S.C.; McCullough, B.; Gao, G.; Wilson, J.M. Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 1999, 73, 3994–4003.
57. Halbert, C.L.; Allen, J.M.; Miller, A.D. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J. Virol. 2001, 75, 6615–6624.
58. Zabner, J.; Seiler, M.; Walters, R.; Kotin, R.M.; Fulgeras, W.; Davidson, B.L.; Chiorini, J.A. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J. Virol. 2000, 74, 3852–3858.
59. Fan, D.S.; Ogawa, M.; Fujimoto, K.I.; Ikeguchi, K.; Ogasawara, Y.; Urabe, M.; Nishizawa, M.; Nakano, I.; Yoshida, M.; Nagatsu, I.; et al. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum. Gene Ther. 1998, 9, 2527–2535.
60. Herzog, R.W.; Hagstrom, J.N.; Kung, S.H.; Tai, S.J.; Wilson, J.M.; Fisher, K.J.; High, K.A. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl. Acad. Sci. USA 1997, 94, 5804–5809.
61. Flotte, T.R.; Afione, S.A.; Conrad, C.; McGrath, S.A.; Solow, R.; Oka, H.; Zeitlin, P.L.; Guggino, W.B.; Carter, B.J. Stable in vivo expression of the cystic fibrosis transmembrane
conductance regulator with an adeno-associated virus vector. *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 10613–10617.

62. During, M.J.; Xu, R.; Young, D.; Kaplitt, M.G.; Sherwin, R.S.; Leone, P. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. *Nat. Med.* **1998**, *4*, 1131–1135.

63. Snyder, R.O.; Miao, C.H.; Patijn, G.A.; Spratt, S.K.; Danos, O.; Nagy, D.; Gown, A.M.; Winther, B.; Meuse, L.; Cohen, L.K.; *et al.* Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. *Nat. Genet.* **1997**, *16*, 270–276.

64. Lewin, A.S.; Drenser, K.A.; Hauswirth, W.W.; Nishikawa, S.; Yasumura, D.; Flannery, J.G.; LaVail, M.M. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. *Nat. Med.* **1998**, *4*, 967–971.

65. Urabe, M.; Ding, C.; Kotin, R.M. Insect cells as a factory to produce adeno-associated virus type 2 vectors. *Hum. Gene Ther.* **2002**, *13*, 1935–1943.

66. Kotin, R.M. Large-scale recombinant adeno-associated virus production. *Hum. Mol. Genet.* **2011**, *20*, R2–R6.

67. Choi, V.W.; McCarty, D.M.; Samulski, R.J. AAV hybrid serotypes: Improved vectors for gene delivery. *Curr. Gene Ther.* **2005**, *5*, 299–310.

68. Donsante, A.; Vogler, C.; Muzyczka, N.; Crawford, J.M.; Barker, J.; Flotte, T.; Campbell-Thompson, M.; Daly, T.; Sands, M.S. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. *Gene Ther.* **2001**, *8*, 1343–1346.

69. Li, H.; Malani, N.; Hamilton, S.R.; Schlachterman, A.; Bussadori, G.; Edmonson, S.E.; Shah, R.; Arruda, V.R.; Mingozzi, F.; Wright, J.F.; *et al.* Assessing the potential for AAV vector genotoxicity in a murine model. *Blood* **2011**, *117*, 3311–3319.

70. Kaplitt, M.G.; Feigin, A.; Tang, C.; Fitzsimons, H.L.; Mattis, P.; Lawlor, P.A.; Bland, R.J.; Young, D.; Strybing, K.; Eidelberg, D.; *et al.* Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: An open label, phase I trial. *Lancet* **2007**, *369*, 2097–2105.

71. Mandel, R.J. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer’s disease. *Curr. Opin. Mol. Ther.* **2010**, *12*, 240–247.

72. Shimada, M.; Abe, S.; Takahashi, T.; Shiozaki, K.; Okuda, M.; Mizukami, H.; Klinman, D.M.; Ozawa, K.; Okuda, K. Prophylaxis and treatment of Alzheimer’s disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein. *PLoS One* **2013**, *8*, e57606.

73. Jessup, M.; Greenberg, B.; Mancini, D.; Cappola, T.; Pauly, D.F.; Jaski, B.; Yaroshinsky, A.; Zsebo, K.M.; Dittrich, H.; Hajjar, R.J.; *et al.* Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca^{2+}-ATPase in patients with advanced heart failure. *Circulation* **2011**, *124*, 304–313.

74. Carter, B.J. Adeno-associated virus vectors in clinical trials. *Hum. Gene Ther.* **2005**, *16*, 541–550.

75. Xin, K.Q.; Urabe, M.; Yang, J.; Nomiyama, K.; Mizukami, H.; Hamajima, K.; Nomiyama, H.; Saito, T.; Imai, M.; Monahan, J.; *et al.* A novel recombinant adeno-associated virus vaccine
induces a long-term humoral immune response to human immunodeficiency virus. *Hum. Gene Ther.* 2001, 12, 1047–1061.

76. Xin, K.Q.; Ooki, T.; Mizukami, H.; Hamajima, K.; Okudela, K.; Hashimoto, K.; Kojima, Y.; Jounai, N.; Kumamoto, Y.; Sasaki, S.; *et al.* Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses. *Hum. Gene Ther.* 2002, 13, 1571–1581.

77. Xin, K.Q.; Mizukami, H.; Urabe, M.; Toda, Y.; Shinoda, K.; Yoshida, A.; Oomura, K.; Kojima, Y.; Ichino, M.; Klinman, D.; *et al.* Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. *J. Virol.* 2006, 80, 11899–11910.

78. Lin, J.; Calcedo, R.; Vandenbergh, L.H.; Bell, P.; Somanathan, S.; Wilson, J.M. A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque. *J. Virol.* 2009, 83, 12738–12750.

79. Nieto, K.; Stahl-Hennig, C.; Leuchs, B.; Muller, M.; Gissmann, L.; Kleinschmidt, J.A. Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. *Hum. Gene Ther.* 2012, 23, 733–741.

80. Ram, Z.; Culver, K.W.; Oshiro, E.M.; Viola, J.J.; DeVroom, H.L.; Otto, E.; Long, Z.; Chiang, Y.; McGarry, G.J.; Muul, L.M.; *et al.* Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. *Nat. Med.* 1997, 3, 1354–1361.

81. Gaspar, H.B.; Parsley, K.L.; Howe, S.; King, D.; Gilmour, K.C.; Sinclair, J.; Brouns, G.; Schmidt, M.; Von Kalle, C.; Barington, T.; *et al.* Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. *Lancet* 2004, 364, 2181–2187.

82. Li, Z.; Dullmann, J.; Schiedlmeier, B.; Schmidt, M.; von Kalle, C.; Meyer, J.; Forster, M.; Stocking, C.; Wahlers, A.; Frank, O.; *et al.* Murine leukemia induced by retroviral gene marking. *Science* 2002, 296, doi:10.1126/science.1068893.

83. Modlich, U.; Kustikova, O.S.; Schmidt, M.; Rudolph, C.; Meyer, J.; Li, Z.; Kamino, K.; von Neuhoff, N.; Schlegelberger, B.; Kuehleke, K.; *et al.* Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. *Blood* 2005, 105, 4235–4246.

84. Maruggi, G.; Porcellini, S.; Facchini, G.; Perna, S.K.; Cattoglio, C.; Sartori, D.; Ambrosi, A.; Schambach, A.; Baum, C.; Bonini, C.; *et al.* Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. *Mol. Ther.* 2009, 17, 851–856.

85. Montini, E.; Cesana, D.; Schmidt, M.; Sanvito, F.; Bartholomae, C.C.; Ranzani, M.; Benedicenti, F.; Sergi, L.S.; Ambrosi, A.; Ponzoni, M.; *et al.* The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. *J. Clin. Invest.* 2009, 119, 964–975.

86. Thornhill, S.I.; Schambach, A.; Howe, S.J.; Ulaganathan, M.; Grassman, E.; Williams, D.; Schiedlmeier, B.; Sebire, N.J.; Gaspar, H.B.; Kinnon, C.; *et al.* Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. *Mol. Ther.* 2008, 16, 590–598.
87. Schroers, R.; Sinha, I.; Segall, H.; Schmidt-Wolf, I.G.; Rooney, C.M.; Brenner, M.K.; Sutton, R.E.; Chen, S.Y. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol. Ther. 2000, 1, 171–179.

88. Kobinger, G.P.; Weiner, D.J.; Yu, Q.C.; Wilson, J.M. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat. Biotechnol. 2001, 19, 225–230.

89. Watson, D.J.; Kobinger, G.P.; Passini, M.A.; Wilson, J.M.; Wolfe, J.H. Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol. Ther. 2002, 5, 528–537.

90. Frecha, C.; Costa, C.; Negre, D.; Gauthier, E.; Russell, S.J.; Cosset, F.L.; Verhoeyen, E. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 2008, 112, 4843–4852.

91. Sinn, P.L.; Hickey, M.A.; Staber, P.D.; Dylla, D.E.; Jeffers, S.A.; Davidson, B.L.; Sanders, D.A.; McCray, P.B., Jr. Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha. J. Virol. 2003, 77, 5902–5910.

92. Pistello, M.; Bonci, F.; Zabogli, E.; Conti, F.; Freer, G.; Maggi, F.; Stevenson, M.; Bendinelli, M. Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus. J. Virol. 2010, 84, 3845–3856.

93. Chiuppesi, F.; Vannucci, L.; de Luca, A.; Lai, M.; Matteoli, B.; Freer, G.; Manservigi, R.; Ceccherini-Nelli, L.; Maggi, F.; Bendinelli, M.; et al. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections. J. Virol. 2012, 86, 6563–6574.

94. Hansen, S.G.; Sacha, J.B.; Hughes, C.M.; Ford, J.C.; Burwitz, B.J.; Scholz, I.; Gilbride, R.M.; Lewis, M.S.; Gilliam, A.N.; Ventura, A.B.; et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 2013, 340, doi:10.1126/science.1237874.

95. Hara, H.; Haru, H.; Hironaka, T.; Inoue, M.; Iida, A.; Shu, T.; Hasegawa, M.; Nagai, Y.; Falsey, A.R.; Kamali, A.; et al. Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: Implications for AIDS vaccine development using Sendai virus vectors. Hum. Vaccin. 2011, 7, 639–645.

96. Moriya, C.; Horiba, S.; Kurihara, K.; Kamada, T.; Takahara, Y.; Inoue, M.; lida, A.; Hara, H.; Shu, T.; Hasegawa, M.; et al. Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies. Vaccine 2011, 29, 8557–8563.

97. Nakanishi, M.; Otsu, M. Development of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine. Curr. Gene Ther. 2012, 12, 410–416.

98. Shimada, M.; Wang, H.B.; Kondo, A.; Xu, X.P.; Yoshida, A.; Shinoda, K.; Ura, T.; Mizuguchi, H.; Klinman, D.; Luo, J.L.; et al. Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy. Gene Ther. 2009, 16, 218–228.

99. Wang, H.B.; Kondo, A.; Yoshida, A.; Yoshizaki, S.; Abe, S.; Bao, L.L.; Mizuki, N.; Ichino, M.; Klinman, D.; Okuda, K.; et al. Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys. Gene Ther. 2010, 17, 4–13.
100. Yashima, S.; Yoshizaki, S.; Shinoda, K.; Yoshida, A.; Kondo, A.; Mizuguchi, H.; Ryo, A.; Okuda, K.; Shimada, M. Co-administration of viral vector-based vaccines suppresses antigen-specific effector CD8 T cells. *Vaccine* **2010**, *28*, 3257–3264.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).